P2.03a-032 Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy

Banna, Giuseppe Luigi; Anile, Giuseppe; Castaing, Marine; Nicolosi, Maria Luisa; Strano, Salvatore; Marletta, F; Calì, Stefania; Lal, Rohit

doi:10.1016/j.jtho.2016.11.1241

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the studies used oral vinorelbine (30 mg, 3 per week) for 35 chemotherapy-naïve patients, yielding an ORR of 26%, median PFS of 4 months, and a median OS of 7 months [190]. In another study applying the same regimen in a similar frail population, median PFS and OS were 2,5 and 5,5 months, respectively [191]. Other regimens were tested for frail, advanced NSLC patients.…”

Section: Resultsmentioning

confidence: 99%

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

Şimşek

Esin

Yalçın

2019

Journal of Oncology

100

View full text Add to dashboard Cite

Metronomic chemotherapy, continuous and dose-dense administration of chemotherapeutic drugs with lowered doses, is being evaluated for substituting, augmenting, or appending conventional maximum tolerated dose regimens, with preclinical and clinical studies for the past few decades. To date, the principle mechanisms of its action include impeding tumoral angiogenesis and modulation of hosts’ immune system, affecting directly tumor cells, their progenitors, and neighboring stromal cells. Its better toxicity profile, lower cost, and easier use are main advantages over conventional therapies. The evidence of metronomic chemotherapy for personalized medicine is growing, starting with unfit elderly patients and also for palliative treatment. The literature reviewed in this article mainly demonstrates that metronomic chemotherapy is advantageous for selected patients and for certain types of malignancies, which make it a promising therapeutic approach for filling in the gaps. More clinical studies are needed to establish a solidified role for metronomic chemotherapy with other treatment models in modern cancer management.

show abstract

Section: Resultsmentioning

confidence: 99%